Your browser is no longer supported. Please, upgrade your browser.
TELA TELA Bio, Inc. daily Stock Chart
TELA Bio, Inc.
Index- P/E- EPS (ttm)-17.10 Insider Own17.50% Shs Outstand11.05M Perf Week9.03%
Market Cap93.37M Forward P/E- EPS next Y-1.84 Insider Trans0.00% Shs Float10.49M Perf Month-28.99%
Income- PEG- EPS next Q-0.56 Inst Own75.30% Short Float1.20% Perf Quarter-35.10%
Sales15.50M P/S6.02 EPS this Y2.60% Inst Trans- Short Ratio2.40 Perf Half Y-
Book/sh2.71 P/B3.12 EPS next Y18.90% ROA- Target Price17.00 Perf Year-
Cash/sh4.94 P/C1.71 EPS next 5Y- ROE- 52W Range5.25 - 18.88 Perf YTD-34.75%
Dividend- P/FCF- EPS past 5Y- ROI-31.30% 52W High-55.24% Beta-
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin60.20% 52W Low60.95% ATR1.33
Employees89 Current Ratio9.60 Sales Q/Q104.20% Oper. Margin- RSI (14)42.60 Volatility7.44% 18.33%
OptionableNo Debt/Eq0.97 EPS Q/Q- Profit Margin- Rel Volume1.38 Prev Close8.48
ShortableYes LT Debt/Eq0.97 EarningsMar 27 BMO Payout- Avg Volume52.49K Price8.45
Recom1.50 SMA205.65% SMA50-32.83% SMA200-33.72% Volume72,354 Change-0.35%
Dec-03-19Initiated Piper Jaffray Overweight
Dec-03-19Initiated JMP Securities Mkt Outperform
Dec-03-19Initiated Jefferies Buy
Dec-03-19Initiated Canaccord Genuity Buy
Mar-30-20 07:29AM  TELA Bio, Inc. (NASDAQ:TELA) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Mar-27-20 07:00AM  TELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
06:00AM  TELA Bio Inc to Host Earnings Call ACCESSWIRE
Mar-11-20 07:00AM  TELA Bio to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 27, 2020 GlobeNewswire -13.39%
Feb-04-20 04:15PM  TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia Repair GlobeNewswire
Jan-29-20 07:00AM  TELA Bio Announces Appointment of New Chief Commercial Officer GlobeNewswire
Jan-10-20 07:00AM  TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 GlobeNewswire
Dec-18-19 07:00AM  TELA Bio Announces Third Quarter 2019 Financial Results GlobeNewswire +11.46%
Dec-06-19 07:00AM  TELA Bio Awarded Contract with HealthTrust Purchasing Group GlobeNewswire
Nov-13-19 04:15PM  TELA Bio Appoints Federica OBrien to Board of Directors GlobeNewswire
04:05PM  TELA Bio Announces Closing of Initial Public Offering of Common Stock GlobeNewswire
Nov-08-19 06:17PM  Chinese Tech News Site 36Kr Flops in Tough Week for U.S. IPOs Bloomberg
Nov-07-19 08:00PM  TELA Bio Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company provides a portfolio of OviTex Reinforced Tissue Matrix or OviTex products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix or OviTex PRS products to address the unmet needs in plastic and reconstructive surgery. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.